A disconnection between hsCRP, ALT and histological benefit was observed in the recent phase 2 CENTAUR trial of the CCR2/CCR5 antagonist cenicriviroc for treatment of NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.